Top Markets
Coin of the day
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
Clasificación en acciones #39524
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Precio por acción
$0.056
Última sincronización: 2023-08-21
Capitalización bursátil
$451.38K
Cambio (1 día)
8.74%
Cambio (1 año)
0.00%
País
US
Comercio Novan, Inc. (NOVN)

Categoría

Historial de rendimiento por dividendo de Novan, Inc. (NOVN)
Rendimiento por dividendo (TTM) de Novan, Inc. (símbolo bursátil: NOVN) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Novan, Inc. (NOVN) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE